Adherence to prescribed Acamprosate® in alcohol dependence and 1-year morbidities and mortality : utilizing a data linkage methodology
MetadataShow full item record
Altmetrics Handle Statistics
Altmetrics DOI Statistics
Objectives: We tested the hypothesis that poor adherence is associated with a greater risk of alcohol-caused mortality and morbidities within the first year of discontinuing this medication. Materials and Methods: A retrospective cohort study of 3319 individuals who received acamprosate in the East of Scotland in a 10-year period was conducted using a health informatics approach with record linkage of dispensing data, hospital utilization (SMR) and General Register Office of Scotland (GROS) data. The primary outcome was adherence between one to six months after initiating acamprosate medication. The secondary outcome was all-cause morbidities and mortality. Results: Of the total 3319 individuals identified, a good adherence index of >80% was found in 59% of those prescribed acamprosate after three months and 6% after six months. There were significant linear trends of poorer adherence with increased risk of alcohol-caused mortality (Hazard Ratio, HR 1.2), medical morbidities especially neoplasm (HR 4.1) and poisoning (HR 1.4), and psychiatric morbidities especially stress (HR 35.1), psychotic (HR 5.6) and neurotic disorders, and directly alcohol induced conditions (7.4 HR) after adjustment for other factors within a one-year period of initiation of acamprosate treatment. Discussion and Conclusions: Further exploratory studies using this digitalized approach should be encouraged in order to capture role of compliance to acamprosate and other types of medication that are known to reduce relapse into alcohol dependence and its direct relationship to mortality and morbidities in this population.
Tolomeo , S & Baldacchino , A M 2021 , ' Adherence to prescribed Acamprosate® in alcohol dependence and 1-year morbidities and mortality : utilizing a data linkage methodology ' , Journal of Clinical Medicine , vol. 10 , no. 10 , 2102 . https://doi.org/10.3390/jcm10102102
Journal of Clinical Medicine
Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
DescriptionThis research was funded by Investigator Sponsored Trial (ISTBAL26102012) provided by Merck Serono Ltd.
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.